Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease.

OBJECTIVE To evaluate retinal toxicity in patients treated with high-dose hydroxychloroquine (HCQ) (Plaquenil, Sanofi Pharmaceuticals) for chronic graft-versus-host disease (GVHD). DESIGN Cohort study. PARTICIPANTS Twelve patients with chronic GVHD treated with 800 mg/day HCQ between June 2005 and December 2010. METHODS Patients in this study underwent ophthalmologic examination yearly and ancillary studies including colour vision, Amsler grid, fundus photographs, Humphrey 10-2 automated perimetry, spectral-domain optical coherence tomography (SD-OCT), and multifocal electroretinography (mfERG). Evidence of HCQ toxicity was determined by the presence of scotomas in the Amsler grid and Humphrey 10-2 automated perimetry, and confirmed by at least 1 objective test including SD-OCT or mfERG. RESULTS Of the 12 patients, 7 were male and 5 were female. Mean age was 49 years. Mean best corrected visual acuity at baseline was 20/25 and remained 20/25 at final follow-up. Median duration of HCQ treatment was 22.8 months. Median adjusted daily dosage was 11.5 mg/kg/day. Seven patients developed vortex keratopathy. No signs of pigmentary retinopathy or bull's-eye maculopathy were found in any of the patients. Three patients developed retinal toxicity with scotomas in the Amsler grid and Humphrey 10-2 automated perimetry, as well as abnormal mfERG. Retinal structure measured by SD-OCT was abnormal in 2 of the 3 patients with retinal toxicity. Colour vision measured by Ishihara plates, as well as by 100 Hue colour test, was abnormal in 2 of the 3 patients with retinal toxicity. CONCLUSIONS High-dose HCQ in patients with GVHD was associated with higher incidence and earlier development of retinal toxicity.

[1]  Arthur D. Fu,et al.  MULTIFOCAL ELECTRORETINOGRAPHY EVALUATION FOR EARLY DETECTION OF RETINAL DYSFUNCTION IN PATIENTS TAKING HYDROXYCHLOROQUINE , 2003, Retina.

[2]  D. Grierson.  Hydroxychloroquine and visual screening in a rheumatology outpatient clinic , 1997, Annals of the rheumatic diseases.

[3]  Mark W. Johnson,et al.  Hydroxychloroquine therapy in massive total doses without retinal toxicity. , 1987, American journal of ophthalmology.

[4]  H. Bernstein.  Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. , 1983, The American journal of medicine.

[5]  J. Jessop,et al.  Screening for hydroxychloroquine retinal toxicity: Is it necessary? , 1990, Eye.

[6]  J. S. Lyons,et al.  Using multifocal ERG ring ratios to detect and follow Plaquenil retinal toxicity: a review , 2009, Documenta Ophthalmologica.

[7]  M. Marmor,et al.  Disparity between visual fields and optical coherence tomography in hydroxychloroquine retinopathy. , 2014, Ophthalmology.

[8]  A. Sadun,et al.  Threshold Amsler grid as a screening tool for asymptomatic patients on hydroxychloroquine therapy , 2005, British Journal of Ophthalmology.

[9]  U. Kellner,et al.  Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. , 2006, Investigative ophthalmology & visual science.

[10]  J. Lupski,et al.  Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease? , 2001, American journal of ophthalmology.

[11]  E. Dubois,et al.  Ocular changes induced by long-term hydroxychloroquine (plaquenil) therapy. , 1967, American journal of ophthalmology.

[12]  R. Rynes.  Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment. , 1983, The American journal of medicine.

[13]  L. A. Runge.  Risk/benefit analysis of hydroxychloroquine sulfate treatment in rheumatoid arthritis. , 1983, The American journal of medicine.

[14]  M. Marmor,et al.  Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. , 2002, Ophthalmology.

[15]  M. Boyer,et al.  Hydroxychloroquine for the treatment of chronic graft-versus-host disease. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  M. Marmor,et al.  Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus , 2010, Arthritis care & research.

[17]  Dennis P. Han,et al.  Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss. , 2009, Transactions of the American Ophthalmological Society.

[18]  P. Grützner.  Acquired color vision defects secondary to retinal drug toxicity. , 1969, Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde.

[19]  M. Mäntyjärvi.  Hydroxychloroquine treatment and the eye. , 1985, Scandinavian journal of rheumatology.

[20]  R. Vij,et al.  A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  M. Easterbrook.  The ocular safety of hydroxychloroquine. , 1993, Seminars in arthritis and rheumatism.

[22]  R. Carr,et al.  Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. , 2002, Ophthalmology.

[23]  M. Easterbrook.  Ocular effects and safety of antimalarial agents. , 1988, The American journal of medicine.

[24]  T. Lai,et al.  Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. , 2005, American journal of ophthalmology.

[25]  Erich E. Sutter,et al.  The field topography of ERG components in man—I. The photopic luminance response , 1992, Vision Research.

[26]  U. Kellner,et al.  Spectral domain optical coherence tomography detects early stages of chloroquine retinopathy similar to multifocal electroretinography, fundus autofluorescence and near-infrared autofluorescence , 2009, British Journal of Ophthalmology.

[27]  L. Mayer,et al.  Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. , 1993, The Journal of rheumatology.

[28]  A. Kwok,et al.  Ocular toxicity of hydroxychloroquine. , 2006, Hong Kong medical journal = Xianggang yi xue za zhi.

[29]  M. Easterbrook.  Screening for antimalarial toxicity: current concepts. , 2002, Canadian Journal of Ophthalmology-journal Canadien D Ophtalmologie.

[30]  D. Newsome,et al.  Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. , 1985, The Journal of rheumatology.

[31]  R. Tehrani,et al.  Ocular Toxicity of Hydroxychloroquine , 2008, Seminars in ophthalmology.

[32]  R. Vij,et al.  Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  H. Bernstein.  Ocular safety of hydroxychloroquine. , 1991, Annals of ophthalmology.

[34]  R Storb,et al.  Bone-marrow transplantation (first of two parts). , 1975, The New England journal of medicine.

[35]  D. Yocum,et al.  Hydroxychloroquine in the treatment of rheumatoid arthritis. , 1983, The American journal of medicine.

[36]  J. Esdaile,et al.  Discontinuation of antimalarial drugs in systemic lupus erythematosus. , 1999, The Journal of rheumatology.

[37]  Maciej Wojtkowski,et al.  High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. , 2007, Archives of ophthalmology.

[38]  Petros P Sfikakis,et al.  The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. , 2003, Ophthalmology.

[39]  Gerald. D. Levy,et al.  Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. , 1997, Arthritis and rheumatism.

[40]  W. Jaeger.  [Acquired colour-vision-deficiencies caused by side-effects of pharmacotherapy (author's transl)]. , 1977, Klinische Monatsblatter fur Augenheilkunde.